Related Experiment Video
Updated: Jul 15, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
VprBP/DCAF1 Triggers Melanomagenic Gene Silencing through Histone H2A Phosphorylation
Yonghwan Shin1, Sungmin Kim1, Gangning Liang2
1Department of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Abstract:
Vpr binding protein (VprBP), also known as DDB1- and CUL4-associated factor1 (DCAF1), is a recently identified atypical kinase and plays an important role in downregulating the transcription of tumor suppressor genes as well as increasing the risk for colon and prostate cancers. Melanoma is the most aggressive form of skin cancer arising from pigment-producing melanocytes and is often associated with the dysregulation of epigenetic factors targeting histones. Here, we demonstrate that VprBP is highly expressed and phosphorylates threonine 120 (T120) on histone H2A to drive the transcriptional inactivation of growth-regulatory genes in melanoma cells. As is the case for its epigenetic function in other types of cancers, VprBP acts to induce a gene silencing program dependent on H2AT120 phosphorylation (H2AT120p). The significance of VprBP-mediated H2AT120p is further underscored by the fact that VprBP knockdown- or VprBP inhibitor-induced lockage of H2AT120p mitigates melanoma tumor growth in xenograft models. Collectively, our results establish VprBP-mediated H2AT120p as a key epigenetic signal for melanomagenesis and suggest the therapeutic potential of targeting VprBP kinase activity for effective melanoma treatment.
Insights
Vpr binding protein (VprBP) drives melanoma by phosphorylating histone H2A, silencing growth genes. Inhibiting VprBP kinase activity reduces melanoma tumor growth, offering a potential new treatment.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Oncology
Background:
- Vpr binding protein (VprBP/DCAF1) is an atypical kinase implicated in cancer.
- Melanoma, an aggressive skin cancer, involves epigenetic dysregulation.
- Histone modifications are crucial in cancer gene regulation.
Purpose of the Study:
- To investigate the role of VprBP in melanoma pathogenesis.
- To determine if VprBP phosphorylates histone H2A at threonine 120 (T120).
- To assess the therapeutic potential of targeting VprBP in melanoma.
Main Methods:
- Analysis of VprBP expression in melanoma cells.
- In vitro and in vivo experiments assessing H2AT120 phosphorylation.
- VprBP knockdown and inhibitor studies in melanoma xenograft models.
Main Results:
- VprBP is highly expressed in melanoma cells.
- VprBP phosphorylates H2A at T120, inducing gene silencing and promoting melanoma.
- VprBP inhibition or knockdown significantly reduces melanoma tumor growth.
Conclusions:
- VprBP-mediated H2AT120 phosphorylation is a key epigenetic driver of melanoma.
- Targeting VprBP kinase activity represents a promising therapeutic strategy for melanoma treatment.
More Related Videos
06:22A Screening Method for Identification of Heterochromatin-Promoting Drugs Using Drosophila
Published on: March 12, 2020
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019
Related Concept Videos
Abnormal Proliferation
MAPK Signaling Cascades
Anaphase Promoting Complex
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Epigenetic Regulation
X-chromosome...
DNA Damage can Stall the Cell Cycle